{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:10:46Z","timestamp":1790464246706,"version":"4.1.0"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Atherosclerosis is a complex pathology that involves both metabolic dysfunction and chronic inflammatory process. During the last decade, a considerable progress was achieved in describing the pathophysiological features of atherosclerosis and developing approaches that target the abnormal lipid metabolism and chronic inflammation. However, early events in the arterial wall that initiate the disease development still remain obscure. Finding effective therapeutic targets in these early processes would allow developing methods for disease prevention and, possibly, atherosclerotic plaque regression. Currently, these early events are being actively studied by several research groups. One of the processes that are being investigated is the development of mitochondrial dysfunction, which was demonstrated to be present in the affected areas of the arterial wall. Detection and characterization of mitochondrial dysfunction associated with several chronic human disorders was made possible by the improved methods of studying mitochondrial biology and detecting mitochondrial DNA (mtDNA) mutations. It was found to be involved in several key atherogenic processes, such as oxidative stress, chronic inflammation, and intracellular lipid accumulation. Mitochondrial dysfunction can occur in all types of cells involved in the pathogenesis of atherosclerosis: monocytes and macrophages, smooth muscle cells, lymphocytes, and the endothelial cells. However, therapies that would specifically target the mitochondria to correct mitochondrial dysfunction and neutralize the defective organelles are still remain to be developed and characterized. The aim of this review is to outline the prospects for mitochondrial therapy for atherosclerosis. We discuss mechanisms of mitochondria-mediated atherogenic processes, known mitochondria-targeting therapy strategies, and novel mitochondria-targeting drugs in the context of atherosclerosis.<\/jats:p>","DOI":"10.3389\/fcvm.2021.660473","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T05:15:40Z","timestamp":1620105340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Atherosclerosis as Mitochondriopathy: Repositioning the Disease to Help Finding New Therapies"],"prefix":"10.3389","volume":"8","author":[{"given":"Taisiia","family":"Shemiakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Kai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana V.","family":"Kirichenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina V.","family":"Starodubova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander N.","family":"Orekhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0092-8674(01)00238-0","article-title":"Atherosclerosis","volume":"104","author":"Glass","year":"2001","journal-title":"Cell."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2174\/1381612820666141013150714","article-title":"Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease","volume":"21","author":"Maranhao","year":"2015","journal-title":"CPD"},{"key":"B3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/1570161116666180206111725","article-title":"Screening for rare genetic variants associated with atherosclerosis: opportunity for personalized medicine","volume":"17","author":"Peterlin","year":"2018","journal-title":"CVP"},{"key":"B4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/biomedicines8060166","article-title":"Mitochondrial dysfunction and DNA damage in the context of pathogenesis of atherosclerosis","volume":"8","author":"Shemiakova","year":"2020","journal-title":"Biomedicines"},{"key":"B5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/B978-0-12-813983-7.00009-4","article-title":"Mitochondrial function and stress resilience. In: Chen A, editor","volume-title":"Stress Resilience","author":"Morat\u00f3","year":"2020"},{"key":"B6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0140-6736(06)68970-8","article-title":"Mitochondrial disease","volume":"368","author":"Schapira","year":"2006","journal-title":"The Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.3390\/ijms21093363","article-title":"Mitochondria targeting as an effective strategy for cancer therapy","volume":"21","author":"Ghosh","year":"2020","journal-title":"Int. J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.acvd.2016.04.002","article-title":"Inflammation in atherosclerosis","volume":"109","author":"Taleb","year":"2016","journal-title":"Arch Cardiovasc Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/1876506801205010013","article-title":"LDL as a cause of atherosclerosis","volume":"5","author":"Tomkin","year":"2012","journal-title":"The Open Atheroscl Thromb J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jjcc.2018.05.010","article-title":"Critical roles of inflammation in atherosclerosis","volume":"73","author":"Moriya","year":"2019","journal-title":"J Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1038\/emm.2014.38","article-title":"CD36, a scavenger receptor implicated in atherosclerosis","volume":"46","author":"Park","year":"2012","journal-title":"Exp Mol Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10557-011-6341-5","article-title":"Oxidized LDL, LOX-1 and Atherosclerosis","volume":"25","author":"Mitra","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/9582430","article-title":"Macrophages and their role in Ath-erosclerosis: pathophysiology and transcriptome analysis","volume":"2016","author":"Bobryshev","year":"2016","journal-title":"BioMed Res Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1161\/01.ATV.0000154359.60886.33","article-title":"Two distinct calcium-dependent mitochondrial pathways are involved in oxidized LDL-induced apoptosis","volume":"25","author":"Vindis","year":"2005","journal-title":"Ather Thromb Vasc Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fj.04-2095fje","article-title":"Oxidative stress in atherosclerosis-prone mouse is due to low antioxidant capacity of mitochondria","volume":"19","author":"Oliveira","year":"2005","journal-title":"FASEB J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1124\/pr.115.011502","article-title":"Mitochondrial quality control as a therapeutic target","volume":"68","author":"Suliman","year":"2016","journal-title":"Pharmacol Rev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.biocel.2016.06.015","article-title":"Mitochondrial reactive oxygen species and inflamma-tion: molecular mechanisms, diseases and promising therapies","volume":"81","author":"Rimessi","year":"2016","journal-title":"Int J Biochem Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.5551\/jat.23929","article-title":"Emerging roles of mitochondria ROS in atherosclerotic lesions: causation or association?","volume":"21","author":"Wang","year":"2014","journal-title":"J Atheroscler Thromb"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5487\/TR.2011.27.1.001","article-title":"Lipid peroxidation and its toxicological implications","volume":"27","author":"Nam","year":"2011","journal-title":"Toxicol. Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.addr.2015.12.024","article-title":"Nanotechnology inspired tools for mitochondrial dysfunction related diseases","volume":"99","author":"Wen","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7687083","DOI":"10.1155\/2018\/7687083","article-title":"Defective autophagy in atherosclerosis: to die or to senesce?","volume":"2018","author":"Grootaert","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1161\/01.RES.0000258450.44413.96","article-title":"Mitochondrial dysfunction in atherosclerosis","volume":"100","author":"Madamanchi","year":"2007","journal-title":"Circ Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1161\/01.res.86.9.960","article-title":"Hydrogen peroxide\u2013and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells","volume":"86","author":"Ballinger","year":"2000","journal-title":"Circ Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"104412","DOI":"10.1016\/j.yexmp.2020.104412","article-title":"The alterations of mitochondrial DNA in coronary heart disease","volume":"114","author":"Hu","year":"2020","journal-title":"Exp Mol Pathol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1161\/CIRCULATIONAHA.113.002271","article-title":"Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans","volume":"128","author":"Yu","year":"2013","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e00584","DOI":"10.1002\/prp2.584","article-title":"Lipid-based gene delivery to macrophage mitochondria for atherosclerosis therapy","volume":"8","author":"Zakirov","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"B27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/heartjnl-2013-304657","article-title":"Mitochondrial cytopathies and cardiovascular disease","volume":"100","author":"Dominic","year":"2014","journal-title":"Heart"},{"key":"B28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00441-008-0678-5","article-title":"Vascular endothelium in atherosclerosis","volume":"335","author":"Sima","year":"2009","journal-title":"Cell Tissue Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1089\/dna.2018.4552","article-title":"Mitochondrial dysfunction in atherosclerosis","volume":"38","author":"Peng","year":"2019","journal-title":"DNA Cell Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"R283","DOI":"10.1093\/hmg\/ddi270","article-title":"Emerging functions of mammalian mitochondrial fusion and fission","volume":"14","author":"Chen","year":"2005","journal-title":"Hum Mol Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"B8","DOI":"10.1016\/S1520-765X(02)90009-X","article-title":"Inflammation in acute coronary syndromes","volume":"4","author":"Maseri","year":"2002","journal-title":"Eur Heart J Suppl"},{"key":"B32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1161\/CIRCRESAHA.114.302153","article-title":"Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-\u03baB\u2013mediated inflammation in macrophages","volume":"114","author":"Wang","year":"2014","journal-title":"Circ Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1152\/physrev.00024.2005","article-title":"Cytokines in atherosclerosis: pathogenic and regulatory pathways","volume":"86","author":"Tedgui","year":"2006","journal-title":"Physiol Rev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.tips.2012.03.010","article-title":"Mitochondrial pharmacology","volume":"33","author":"Smith","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1042\/BJ20110162","article-title":"Assessing mitochondrial dysfunction in cells","volume":"435","author":"Brand","year":"2011","journal-title":"Biochem J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000446586","article-title":"Primary mitochondrial disease and secondary mitochondrial dysfunction: importance of distinction for diagnosis and treatment","volume":"7","author":"Niyazov","year":"2016","journal-title":"Mol Syndromol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pharmthera.2013.07.011","article-title":"Mitochondrial bioenergetics and therapeutic intervention in cardiovascular disease","volume":"141","author":"Mercer","year":"2014","journal-title":"Pharmacol Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.20517\/2574-1209.2017.16","article-title":"New markers of atherosclerosis: a threshold level of heteroplasmy in mtDNA mutations","volume":"1","author":"Sazonova","year":"2017","journal-title":"Vessel Plus"},{"key":"B39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10545-010-9122-6","article-title":"Altering the balance between healthy and mutated mitochondrial DNA","volume":"34","author":"Smith","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"13323","DOI":"10.1074\/jbc.M113.528968","article-title":"Modeling of antigenomic therapy of mitochondrial diseases by mitochondrially addressed RNA targeting a pathogenic point mutation in mitochondrial DNA","volume":"289","author":"Tonin","year":"2014","journal-title":"J Biol Chem"},{"key":"B41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/bs.pmbts.2020.12.009","article-title":"Mitochondrial DNA modification by CRISPR\/Cas system: challenges and future direction","volume":"178","author":"Prakash","year":"2021","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B42","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1021\/acs.molpharmaceut.6b00823","article-title":"Mitochondrial gene therapy: advances in mitochondrial gene cloning, plasmid production, and nanosystems targeted to mitochondria","volume":"14","author":"Coutinho","year":"2017","journal-title":"Mol Pharm"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1038\/s41598-018-20838-8","article-title":"OPA1 gene therapy prevents retinal ganglion cell loss in a dominant optic atrophy mouse model","volume":"8","author":"Sarzi","year":"2018","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","article-title":"Proteasome inhibitors in cancer therapy: lessons from the first decade","volume":"14","author":"Orlowski","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jacc.2012.08.1021","article-title":"Mitochondria as a therapeutic target in heart failure","volume":"61","author":"Bayeva","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.trsl.2017.09.003","article-title":"Metformin attenuates ER stress\u2013induced mitochondrial dysfunc-tion","volume":"190","author":"Chen","year":"2017","journal-title":"Transl Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.mce.2016.06.008","article-title":"Metformin and resveratrol inhibit Drp1-mediated mitochondrial fission and prevent ER stress-associated NLRP3 inflammasome activation in the adipose tissue of diabetic mice","volume":"434","author":"Li","year":"2016","journal-title":"Mol Cell Endocrinol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jconrel.2015.10.023","article-title":"Delivery of drugs and macromolecules to the mitochondria for cancer therapy","volume":"240","author":"Lu","year":"2016","journal-title":"J Control Release."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1089\/ars.2011.3969","article-title":"Mitochondria-targeted small molecule therapeutics and probes","volume":"15","author":"Smith","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1021\/ar4000554","article-title":"Fifteen years of cell-penetrating, guanidinium-rich molecular transporters: basic science, research tools, and clinical applications","volume":"46","author":"Stanzl","year":"2013","journal-title":"Acc Chem Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2012.05.014","article-title":"Targeting drugs to mitochondria","volume":"82","author":"Heller","year":"2012","journal-title":"Eur. J Pharm Biopharm"},{"key":"B52","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00421-002-0745-7","article-title":"Dynamic changes of deleted mitochondrial DNA in human leucocytes after endurance exercise","volume":"88","author":"Iwai","year":"2003","journal-title":"Eur J Appl Physiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13395-016-0075-9","article-title":"Exercise-induced mitochondrial p53 repairs mtDNA mutations in mutator mice","volume":"6","author":"Safdar","year":"2015","journal-title":"Skeletal Muscle."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.3390\/molecules23113016","article-title":"Improving the phototherapeutic efficiencies of molecular and nanoscale materials by targeting mitochondria","volume":"23","author":"Lin","year":"2018","journal-title":"Molecules"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2147\/JIR.S275595","article-title":"Reactive oxygen species: drivers of physiological and pathological processes","volume":"13","author":"Checa","year":"2020","journal-title":"J Inflamm Rex"},{"key":"B56","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2174\/138161207780363077","article-title":"Targeting antioxidants to mitochondria: a potential new therapeutic strategy for cardiovascular diseases","volume":"13","author":"Victor","year":"2007","journal-title":"Curr Pharm Des"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/342806","article-title":"Protectors or traitors: the roles of PON2 and PON3 in atherosclerosis and cancer","volume":"2012","author":"Witte","year":"2012","journal-title":"J Lipids"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.numecd.2020.02.014","article-title":"Protective effects of luteolin against oxidative stress and mitochondrial dysfunction in endothelial cells","volume":"30","author":"Chen","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.2174\/138161210793292519","article-title":"Mitochondria-targeted an-tioxidant peptides","volume":"16","author":"Rocha","year":"2010","journal-title":"Curr Pharm Des"},{"key":"B60","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/biology9030060","article-title":"Oxidative stress and anti-oxidants in atherosclerosis development and treatment","volume":"9","author":"Poznyak","year":"2020","journal-title":"Biology"},{"key":"B61","doi-asserted-by":"publisher","first-page":"H13","DOI":"10.1152\/ajpheart.00368.2009","article-title":"Resveratrol induces mitochondrial biogenesis in endothelial cells","volume":"297","author":"Csiszar","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1161\/CIRCULATIONAHA.111.066589","article-title":"Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport","volume":"125","author":"Rosenson","year":"2012","journal-title":"Circulation"},{"key":"B63","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1161\/CIRCRESAHA.117.305624","article-title":"Macrophage mitochondrial energy status regulates cholesterol efflux and is enhanced by an-ti-miR33 in atherosclerosis","volume":"117","author":"Karunakaran","year":"2015","journal-title":"Circ Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1161\/CIRCRESAHA.111.300233","article-title":"Mitochondria and endothelial function","volume":"112","author":"Kluge","year":"2013","journal-title":"Circ Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/1561342","article-title":"NLRP3 inflammasome: a potential alternative therapy target for atherosclerosis","volume":"2020","author":"Liu","year":"2020","journal-title":"Evid Based Complement Altern Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.immuni.2013.08.001","article-title":"Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation","volume":"39","author":"Iyer","year":"2013","journal-title":"Immunity"},{"key":"B67","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.vph.2015.07.004","article-title":"Salidroside improves endothelial function and alleviates atherosclerosis by activating a mitochondria-related AMPK\/PI3K\/Akt\/eNOS pathway","volume":"72","author":"Xing","year":"2015","journal-title":"Vasc Pharmacol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"101373","DOI":"10.1016\/j.redox.2019.101373","article-title":"Anti-inflammatory cytokines IL-35 and IL-10 block atherogenic lysophosphatidylcholine-induced, mitochondrial ROS-mediated innate immune activation, but spare innate immune memory signature in endothelial cells","volume":"28","author":"Li","year":"2020","journal-title":"Redox Biol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"9445","DOI":"10.1073\/pnas.1301929110","article-title":"Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis","volume":"110","author":"Marrache","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B70","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.chemosphere.2018.06.170","article-title":"Silica nanoparticles induced endothelial apoptosis via endoplasmic reticulum stress-mitochondrial apoptotic signaling pathway","volume":"210","author":"Guo","year":"2018","journal-title":"Chemosphere"},{"key":"B71","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2174\/138161282601200225102449","article-title":"Current trends in vascular biology and atherothrombosis","volume":"26","author":"Sobenin","year":"2020","journal-title":"Curr Pharm Des"},{"key":"B72","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1161\/CIRCRESAHA.115.306300","article-title":"MicroRNA regulation of atherosclerosis","volume":"118","author":"Feinberg","year":"2016","journal-title":"Circ Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/s41440-020-0423-3","article-title":"MitomiRs: new emerging microRNAs in mitochondrial dysfunction and cardiovascular disease","volume":"43","author":"Paramasivam","year":"2020","journal-title":"Hypertens Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1089\/ars.2020.8107","article-title":"MicroRNAs as master regulators of atherosclerosis: from pathogenesis to novel therapeutic options","volume":"33","author":"Hosen","year":"2020","journal-title":"Antioxid Redox Signal"},{"key":"B75","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1161\/CIRCRESAHA.114.302355","article-title":"Atherosclerotic plaque destabilization","volume":"114","author":"Silvestre-Roig","year":"2014","journal-title":"Circ Res"},{"key":"B76","doi-asserted-by":"publisher","first-page":"28821","DOI":"10.18632\/oncotarget.8936","article-title":"Mitophagy acts as a safeguard mechanism against human vascular smooth muscle cell apoptosis induced by atherogenic lipids","volume":"7","author":"Swiader","year":"2016","journal-title":"Oncotarget"},{"key":"B77","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/cells8060638","article-title":"The multifunctional sorting protein PACS-2 controls mitophagosome formation in human vascular smooth muscle cells through mitochondria-ER contact sites","volume":"8","author":"Moulis","year":"2019","journal-title":"Cells"},{"key":"B78","doi-asserted-by":"publisher","first-page":"2819658","DOI":"10.1155\/2020\/2819658","article-title":"Gypenoside inhibits endothelial cell apoptosis in atherosclerosis by modulating mitochondria through PI3K\/Akt\/Bad pathway","volume":"2020","author":"Song","year":"2020","journal-title":"Biomed. Res. Int"},{"key":"B79","first-page":"RA132","article-title":"Targeting antioxidants to mitochondria and cardiovascular diseases: the effects of mitoquinone","volume":"13","author":"Rocha","year":"2007","journal-title":"Med Sci Monit"},{"key":"B80","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.2174\/092986709789878265","article-title":"Oxidative stress and mitochondrial dysfunction in atherosclerosis: mitochondria-targeted antioxidants as potential therapy","volume":"16","author":"Victor","year":"2009","journal-title":"Curr Med Chem"},{"key":"B81","unstructured":"ParkS-Y\n          Impacts of Mitochondrial-Targeted Antioxidant on Leg Blood Flow and Skeletal Muscle Mitochondrial Function in Peripheral Artery Disease Patients2018"},{"key":"B82","unstructured":"CreagerMA\n          Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease2013"},{"key":"B83","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2016.01.044","article-title":"Effects of simvastatin, ezetimibe and simvastatin\/ezetimibe on mitochondrial function and leukocyte\/endothelial cell interactions in patients with hypercholesterolemia","volume":"247","author":"Hernandez-Mijares","year":"2016","journal-title":"Atherosclerosis"},{"key":"B84","unstructured":"Targeting Mitochondrial Fusion and Fission to Prevent Atherosclerosis: Getting the Balance Right (MITOFFA)2019"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1089\/ars.2013.5566","article-title":"Tetrahydrobiopterin in cardiovascular health and disease","volume":"20","author":"Bendall","year":"2014","journal-title":"Antioxid Redox Signal"},{"key":"B86","unstructured":"ParkS-Y\n          Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease2018"},{"key":"B87","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2119\/molmed.2014.00195","article-title":"Valsartan attenuates Ath-erosclerosis via upregulating the Th2 immune response in prolonged angiotensin II-treated ApoE\u2013\/\u2013 mice","volume":"21","author":"Meng","year":"2015","journal-title":"Mol Med."},{"key":"B88","unstructured":"Use of Entresto Sacubitril\/Valsartan for the Treatment of Peripheral Arterial Disease2019"},{"key":"B89","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/978-3-319-55330-6_32","article-title":"Mitochondria-targeted antioxidants for the treatment of cardiovascular disorders. In: Santulli G, editor","volume-title":"Mitochondrial Dynamics in Cardiovascular Medicine","author":"Kim","year":"2017"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e005487","DOI":"10.1161\/CIRCINTERVENTIONS.117.005487","article-title":"Phase 2a clinical trial of mitochondrial protection (elamipretide) during stent revascularization in patients with atherosclerotic renal artery stenosis","volume":"10","author":"Saad","year":"2017","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.660473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T05:15:50Z","timestamp":1620105350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.660473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":90,"alternative-id":["10.3389\/fcvm.2021.660473"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.660473","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"article-number":"660473"}}